Pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury

Journal of Clinical Pharmacology

Volumn 43, Issue 4, 2003, Pages 379-385

  Hayes, K C ^a,d   Katz, M A ^b   Devane, J G ^c   Hsieh, J T C ^a   Wolfe, D L ^a   Potter, P J ^a   Blight, A R ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ACORDA THERAPEUTICS INC   (United States)

^c ELAN PHARMACEUTICALS   (United States)

^d ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

4 Aminopyridine pharmacokinetics; Fampridine; Spinal cord injury

Indexed keywords

4 AMINOPYRIDINE;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG RELEASE; DRUG TOLERABILITY; DYSESTHESIA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMEDIATE RELEASE FORMULATION; LETHARGY; MALE; MUSCLE STIFFNESS; NAUSEA; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; RASH; SPINAL CORD INJURY; ULTRAVIOLET RADIATION; VERTIGO;

4-AMINOPYRIDINE; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; POTASSIUM CHANNEL BLOCKERS; SPINAL CORD INJURIES; TIME FACTORS;

EID: 0037380712     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003251388     Document Type: Article

References (54)

1. Hayes KC, Blight AR, Potter PJ, Allatt RD, Hsieh JT, Wolfe DL, et al: Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. Paraplegia 1993;31(4):216-224.
2. Donovan WH, Halter JA, Graves DE, Blight AR, Calvillo O, McCann MT, et al: Intravenous infusion of 4-AP in chronic spinal cord injured subjects. Spinal Cord 2000;38(1):7-15.
3. Halter JA, Blight AR, Donovan WH, Calvillo O: Intrathecal administration of 4-aminopyridine in chronic spinal injured patients. Spinal Cord 2000;38(12):728-732.
4. Hansebout RR, Blight AR, Fawcett S, Reddy K: 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma 1993;10(1):1-18.
5. Hayes KC: 4-Aminopyridine and spinal cord injury: a review. Rest Neurol Neurosci 1994;6:259-270.
6. Hayes KC, Potter PJ, Wolfe DL, Hsieh JT, Delaney GA, Blight AR: 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury. J Neurotrauma 1994;11(4):433-446.
7. Segal JL, Brunnemann SR: 4-Aminopyridine improves pulmonary function in quadriplegic humans with longstanding spinal cord injury. Pharmacotherapy 1997;17(3):415-423.
8. Segal JL, Brunnemann SR: 4-Aminopyridine alters gait characteristics and enhances locomotion in spinal cord injured humans. J Spinal Cord Med 1998; 21(3):200-204.
9. Segal JL, Pathak MS, Hernandez JP, Himber PL, Brunnemann SR, Charter RS: Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial. Pharmacotherapy 1999;19(6):713-723.
10. van der Bruggen MA, Huisman HB, Beckerman H, Bertelsmann FW, Polman CH, Lankhorst GJ: Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol 2001;248(8):665-671.
11. Potter PJ, Hayes KC, Hsieh JT, Delaney GA, Segal JL: Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases. Spinal Cord 1998;36(3):147-155.
12. Potter PJ, Hayes KC, Segal JL, Hsieh JT, Brunnemann SR, Delaney GA, et al: Randomized double-blind crossover trial of Fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J Neurotrauma 1998;15(10):837-849.
13. Bever CT Jr, Young D, Anderson PA, Krumholz A, Conway K, Leslie J, et al: The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994;44(6): 1054-1059.
14. Davis FA, Stefoski D, Rush J: Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27(2):186-192.
15. Davis FA, Stefoski D, Quandt FN: Mechanism of action of 4-aminopyridine in the symptomatic treatment of multiple sclerosis. Ann Neurol 1995;37(5):684.
16. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC: 4-Aminopyridine in the treatment of patients with multiple sclerosis: long-term efficacy and safety. Arch Neurol 1994;51(3):292-296.
17. Polman CH, Bertelsmarm FW, de Waal R, Van Diemen HA, Uitdehaag BM, van Loenen AC, et al: 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 1994;51(11):1136-1139.
18. Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD: Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48(4):817-821.
19. Stefoski D, Davis FA, Faut M, Schauf CL: 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987;21(1): 71-77.
20. Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW: 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991;41(9):1344-1348.
21. Van Diemen HA, Polman CH, van Dongen MM, Nauta JJ, Strijers RL, van Loenen AC, et al: 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J Neurol Sci 1993;116(2):220-226.
22. Van Diemen HA, Polman CH, Koetsier JC, van Loenen AC, Nauta JJ, Bertelsmann FW: 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 1993;16(3):195-204.
23. van Diemen HAM, Polman CH, van Dongen TMMM, van Loenen AC, Nauta JJP, Taphoorn MJB, et al: The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized placebo-controlled, double-blind, cross-over study. Ann Neurol 1992;32:123-130.
24. Bostock H, Sears TA, Sherratt RM: The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol 1981;313:301-315.
25. Bowe CM, Kocsis JD, Targ EF, Waxman SG: Physiological effects of 4-aminopyridine on demyelinated mammalian motor and sensory fibers. Ann Neurol 1987;22(2):264-268.
26. Sherratt RM, Bostock H, Sears TA: Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980; 283(7):570-572.
27. Shi R, Blight AR: Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77(2):553-562.
28. Targ EF, Kocsis JD: 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985;328(2): 358-361.
29. Blight AR: Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989;22(1):47-52.
30. Lundh H, Thesleff S: The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals. Eur Pharmacol 1977;42(4):411-412.
31. Jankowska E, Lundberg A, Rudomin P, Sykova E: Effects of 4-aminopyridine on transmission in excitatory and inhibitory synapses in the spinal cord. Brain Res 1977;136(2):387-392.
32. Kirsch GE, Drewe JA: Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels. J Gen Physiol 1993;102(5):797-816.
33. Molgo J, Lemeignan M, Lechat P: Effects of 4-aminopyridine at the frog neuromuscular junction. J Pharmacol Exp Ther 1977;203(3): 653-663.
34. Qiao J, Hayes KC, Hsieh JT, Potter PJ, Delaney GA: Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury. J Neurotrauma 1997;14(3):135-149.
35. Segal JL, Hayes KC, Brunnemann SR, Hsieh JT, Potter PJ, Pathak MS, et al: Absorption characteristics of sustained-release 4-aminopyridine (Fampridine SR) in patients with chronic spinal cord injury. J Clin Pharmacol 2000;40(4):402-409.
36. Ball AP, Hopkinson RB, Farrell ID, Hutchison JG, Paul R, Watson RD, et al: Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak. Q J Med 1979;48(191):473-491.
37. Murray NM, Newsom-Davis J: Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981;31(3):265-271.
38. Wesseling H, Lakke PJWF: Observations with 4-aminopyridine in Huntington's chorea. IRCS J Med Sci 1980;8:322-333.
39. Wesseling H, Agoston S, Van Dam GB, Pasma J, DeWit DJ, Havinga H: Effects of 4-aminopyridine in elderly patients with Alzheimer's disease. N Engl J Med 1984;310(15):988-989.
40. Smeets JW, Kunst MWL Severe poisoning by 4-aminopyridine in a body builder. Ned Tijdschr Geneeskd 1995;139(51):2667-2669.
41. Spyker DA, Lynch C, Shabanowitz J, Sinn JA: Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 1980;16(4): 487-497.
42. Stork CM, Hoffman RS: Characterization of 4-aminopyridine in overdose. J Toxicol Clin Toxicol 1994;32(5):583-587,
43. Evenhuis J, Agoston S, Salt PJ, de Lange AR, Wouthuyzen W, Erdmann W: Pharmacokinetics of 4-aminopyridine in human volunteers: a preliminary study using a new GLC method for its estimation. Br J Anaesth 1981;53(6):567-570.
44. Uges DR, Sohn YJ, Greijdanus B, Scaf AH, Agoston S: 4-Aminopyridine kinetics. Clin Pharmacol Ther 1982;31(5):587-593.
45. Pongs O: Molecular biology of voltage-dependent potassium channels. Physiol Rev 1992;72(4, Suppl.):S69-S88.
46. Agoston S, Maestrone E, van Hezik EJ, Ket JM, Houwertjes MC, Uges DR: Effective treatment of verapamil intoxication with 4-aminopyridine in the cat. J Clin Invest 1984;73(5):1291-1296.
47. Gay R, Algeo S, Lee R, Olajos M, Morkin E, Goldman S: Treatment of verapamil toxicity in intact dogs. J Clin Invest 1986;77(6):1805-1811.
48. Hatch RC, Kitzman JV, Zahner JM, Clark JD: Antagonism of xylazine sedation with yohimbine, 4-aminopyridine, and doxapram in dogs. Am J Vet Res 1985;46(2):371-375.
49. Miller RD, Booij LH, Agoston S, Crul JF: 4-Aminopyridine potentiates neostigmine and pyridostigmine in man. Anesthesiology 1979;50(5):416-420.
50. Sia RL, Salt PJ, Langrehr D, Agoston S, Erdmann W: Effects of the analeptic drug, 4-aminopyridine, upon post-operative respiratory depression in patients: a preliminary study. Acta Anaesthesiol Belg 1979;30(Suppl.):195-199.
51. Bugaresti JM, Hansebout RR, Katz MA, Blight AR: Pharmacokinetics and safety of single oral doses of Fampridine-SR (sustained-release 4-aminopyridine) tablets in patients with chronic spinal cord injury. Arch Phys Med Rehabil 2001;82:1337.
52. Fujihara K, Miyoshi T: The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis. J Neurol Sci 1998;159(1):102-106.
53. Wolfe DL, Hayes KC, Hsieh JT, Potter PJ: Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: a double-blinded, placebo-controlled crossover trial. Neurotrauma 2001;18(8):757-771.
54. Greenberg RN: Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6(5):592-599.